149 related articles for article (PubMed ID: 33523584)
21. Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer.
Liu J; Lei B; Yu X; Li Y; Deng Y; Yang G; Li Z; Liu T; Ye L
Front Immunol; 2022; 13():888339. PubMed ID: 35911730
[TBL] [Abstract][Full Text] [Related]
22. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
23. Prognostic stromal gene signatures in breast cancer.
Winslow S; Leandersson K; Edsjö A; Larsson C
Breast Cancer Res; 2015 Feb; 17(1):23. PubMed ID: 25848820
[TBL] [Abstract][Full Text] [Related]
24. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
25. Kinome expression profiling and prognosis of basal breast cancers.
Sabatier R; Finetti P; Mamessier E; Raynaud S; Cervera N; Lambaudie E; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2011 Jul; 10():86. PubMed ID: 21777462
[TBL] [Abstract][Full Text] [Related]
26. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
27. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
Buechler SA; Gökmen-Polar Y; Badve SS
Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
[TBL] [Abstract][Full Text] [Related]
28. Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.
Guo X; Zhu SX; Brunner AL; van de Rijn M; West RB
Breast Cancer Res; 2013 Dec; 15(6):R117. PubMed ID: 24342436
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy.
Sjöström M; Chang SL; Fishbane N; Davicioni E; Hartman L; Holmberg E; Feng FY; Speers CW; Pierce LJ; Malmström P; Fernö M; Karlsson P
Clin Cancer Res; 2020 Jan; 26(1):171-182. PubMed ID: 31558478
[TBL] [Abstract][Full Text] [Related]
30. Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment.
Chen B; Zhang S; Li Q; Wu S; He H; Huang J
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33146700
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
32. Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer.
Bao S; Hu T; Liu J; Su J; Sun J; Ming Y; Li J; Wu N; Chen H; Zhou M
J Nanobiotechnology; 2021 Jan; 19(1):22. PubMed ID: 33436002
[TBL] [Abstract][Full Text] [Related]
33. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
Tang W; Xu F; Zhao M; Zhang S
BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
[TBL] [Abstract][Full Text] [Related]
34. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
35. Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations.
Wang DY; Done SJ; Mc Cready DR; Leong WL
Breast Cancer Res; 2014 Jul; 16(4):R71. PubMed ID: 24996446
[TBL] [Abstract][Full Text] [Related]
36. Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.
Todd JR; Ryall KA; Vyse S; Wong JP; Natrajan RC; Yuan Y; Tan AC; Huang PH
Oncotarget; 2016 Sep; 7(39):62939-62953. PubMed ID: 27556857
[TBL] [Abstract][Full Text] [Related]
37. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
38. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes.
Heimes AS; Härtner F; Almstedt K; Krajnak S; Lebrecht A; Battista MJ; Edlund K; Brenner W; Hasenburg A; Sahin U; Gehrmann M; Hengstler JG; Schmidt M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
